Epistem licence Hubrecht Organoid Technology to expand preclinical toxicology service portfolio
Epistem Limited has announced the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB) to enable the delivery of an increased range of multi species organoid models. Services are focused on the identification of off target or off tissue intestinal toxicities associated with various therapeutics.
Epistem completes board line up and launches new NGS service
Epistem Limited, the Manchester based pre-clinical and clinical research services company announces the completion of its Board appointments. Investment from the Foresight group in June 2018 enabled expansion of the research services, the first of which is launched in December 2018 - GCLP compliant Next Generation Sequencing (NGS) services.
10 Years GCLP Accreditation at Epistem
We are pleased to announce the successful GCLP re-accreditation of our laboratories.
Epistem completes management buyout
Epistem, the Manchester UK-based Contract Research Company, announces that following investment by Foresight Group it has completed a management buy-out ("MBO") from genedrive plc.